Market Insights Health Pharmaceuticals Vaccines

Other Vaccines - Western Africa

Western Africa

In Western Africa, the revenue in the market Other Vaccines market is estimated to reach US$117.60m by 2024.
It is anticipated that the revenue will exhibit an annual growth rate (CAGR 2024-2029) of 11.85%, leading to a market volume of US$205.90m by 2029.
When compared globally, United States is expected to generate the highest revenue of US$24,730.00m in 2024.
Despite challenges, Western Africa is experiencing a growing demand for other vaccines due to increased awareness and government initiatives.

Key regions: Australia, Brazil, United Kingdom, Europe, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Other Vaccines market in Western Africa has been experiencing significant growth in recent years.

Customer preferences: The demand for vaccines has been on the rise in Western Africa due to an increase in government initiatives and awareness campaigns aimed at promoting vaccination. Additionally, the region has a high prevalence of infectious diseases, which has led to an increase in the demand for vaccines.

Trends in the market: The market for Other Vaccines in Western Africa has been growing due to the increasing prevalence of infectious diseases such as yellow fever, meningitis, and cholera. These diseases have been responsible for several outbreaks in the region, which has led to an increase in the demand for vaccines. Furthermore, the introduction of new vaccines in the market has also contributed to the growth of the market.

Local special circumstances: The region has witnessed several outbreaks of infectious diseases in recent years, which has led to an increase in the demand for vaccines. The lack of adequate healthcare infrastructure in the region has also contributed to the growth of the market, as vaccines are seen as a cost-effective preventive measure.

Underlying macroeconomic factors: The economic growth in the region has contributed to the growth of the Other Vaccines market. The increase in disposable income has led to an increase in the demand for healthcare services, which has led to an increase in the demand for vaccines. Additionally, the government's efforts to improve healthcare infrastructure have also contributed to the growth of the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.